Merck reported worldwide sales of $18.1 billion for the third quarter of 2026, representing a 5% increase compared to the same period in 2025. GAAP EPS was $2.04 and non-GAAP EPS was $2.49, both impacted by a one-time charge related to a global license agreement with SciBrunch. The company also narrowed and raised its full-year 2026 financial outlook for sales and non-GAAP EPS.
Total worldwide sales reached $18.1 billion in Q3 2026, up 5% from $17.276 billion in Q3 2025.
KEYTRUDA sales grew 6% to $8.6 billion, and WINREVAIR sales surged 93% to $694 million.
Full-year 2026 sales outlook was raised to a range of $66.8 billion to $67.3 billion.
Full-year 2026 non-GAAP EPS outlook was raised to a range of $2.77 to $2.82.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Merck & Co.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$65.01B
+1.3%
$7.28
+8.0%
28.1%
FY2024
$64.17B
+6.7%
$6.74
+4714.3%
26.7%
FY2023
$60.12B
+1.4%
$0.14
-97.5%
0.6%
FY2022
$59.28B
+21.7%
$5.71
+11.1%
24.5%
FY2021
$48.70B
+17.3%
$5.14
+84.9%
26.8%
Frequently asked questions
When is Merck &'s next earnings date?
Merck & has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Merck & earn last quarter?
For the quarter ended Sep 2026, Merck & reported diluted EPS of $2.04 (-12.1% year over year) on revenue of $18.09B (+4.7%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.